Optic neuritis
JL Bennett - Continuum: lifelong learning in neurology, 2019 - journals.lww.com
PURPOSE OF REVIEW This article discusses the clinical presentation, evaluation, and
management of the patient with optic neuritis. Initial emphasis is placed on clinical history …
management of the patient with optic neuritis. Initial emphasis is placed on clinical history …
The clinico-radiological paradox in multiple sclerosis revisited
F Barkhof - Current opinion in neurology, 2002 - journals.lww.com
The use of magnetic resonance imaging as a surrogate outcome measure in clinical trials, or
even as a prognosticator in the assessment of the natural evolution, assumes a close …
even as a prognosticator in the assessment of the natural evolution, assumes a close …
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, San Francisco MS … - Annals of …, 2016 - Wiley Online Library
Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …
Multiple sclerosis: pathogenesis and treatment
I Loma, R Heyman - Current neuropharmacology, 2011 - ingentaconnect.com
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …
central nervous system. It affects approximately 400,000 people in the United States and …
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis
Abstract Information-processing speed (IPS) slowing is a primary cognitive deficit in multiple
sclerosis (MS). Basal ganglia, thalamus and neocortex are thought to have a key role for …
sclerosis (MS). Basal ganglia, thalamus and neocortex are thought to have a key role for …
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N De Stefano, A Giorgio, M Battaglini, M Rovaris… - Neurology, 2010 - AAN Enterprises
Objective: To assess the time course of brain atrophy and the difference across clinical
subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was …
subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was …
The measurement and clinical relevance of brain atrophy in multiple sclerosis
Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and …
A Rae-Grant, GS Day, RA Marrie, A Rabinstein… - Neurology, 2018 - AAN Enterprises
Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …
[HTML][HTML] The diagnosis and treatment of optic neuritis
H Wilhelm, M Schabet - Deutsches Ärzteblatt International, 2015 - ncbi.nlm.nih.gov
Background Typical optic neuritis is often the presenting manifestation of multiple sclerosis
(MS). Its incidence in central Europe is 5 cases per 100 000 persons per year. Methods This …
(MS). Its incidence in central Europe is 5 cases per 100 000 persons per year. Methods This …
Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
C Jacobsen, J Hagemeier, KM Myhr… - Journal of Neurology …, 2014 - jnnp.bmj.com
Objectives To identify MRI biomarkers associated with long-term disability progression in
patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue …
patients with multiple sclerosis (MS), and to define the rate of evolution of global, tissue …